You are here

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation

sandy craine's picture
Submitted by sandy craine on Mon, 10/09/2012 - 1:50pm
Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation Blood. 2012 Aug 15;[Epub Ahead of Print], J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah, N Nanda, AC Benichou, AR Craig, M Michallet, FE Nicolini, H Kantarjian

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation
Blood. 2012 Aug 15;[Epub Ahead of Print], J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah, N Nanda, AC Benichou, AR Craig, M Michallet, FE Nicolini, H Kantarjian

Ariad Prepares for Early Launch of CML Drug Ponatinib The Pink Sheet Daily. 2012 Aug 6, E Hayes

sandy craine's picture
Submitted by sandy craine on Mon, 10/09/2012 - 1:47pm
With an FDA filing of its wholly owned chronic myelogenous leukemia drug ponatinib under its belt, Ariad Pharmaceuticals Inc.says it will be commercially ready in the U.S. by the end of October and hopes to launch in the first quarter of 2013.

With an FDA filing of its wholly owned chronic myelogenous leukemia drug ponatinib under its belt, Ariad Pharmaceuticals Inc.says it will be commercially ready in the U.S. by the end of October and hopes to launch in the first quarter of 2013.

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells

sandy craine's picture
Submitted by sandy craine on Mon, 10/09/2012 - 1:36pm
Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells
Br J Cancer. 2012 May 1;1061772-1778, J Wang, TP Hughes,

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

sandy craine's picture
Submitted by sandy craine on Thu, 16/08/2012 - 4:29pm
'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.

'Results from the ongoing Phase 2 PACE trial of ponatinib reported in June at this year’s annual meeting of the American Society of Clinical Oncology showed that 54 percent of chronic-phase CML patients who were resistant or intolerant to tyrosine kinase inhibitor therapy in the trial, including 70 percent of patients who have a T315I mutation, achieved a major cytogenetic response (MCyR) – the primary endpoint of the PACE trial. Thirty percent of these same patients achieved a major molecular response (MMR). MMR is the primary endpoint of ARIAD’s Phase 3 EPIC trial comparing ponatinib to imatinib that is now underway in newly diagnosed chronic-phase CML patients.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

sandy craine's picture
Submitted by sandy craine on Fri, 06/07/2012 - 2:15pm
Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]

Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85. [Epub ahead of print]

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

sandy craine's picture
Submitted by sandy craine on Tue, 03/07/2012 - 5:55pm
Leukemia advance online publication 15 June 2012; doi: 10.1038/leu.2012.134

Leukemia advance online publication
15 June 2012; doi: 10.1038/leu.2012.134

Pages